Editas reports in vivo POC data for undisclosed liver target; ~70% editing in mice

Editas Medicine, Inc.

Maximal liver editing of ~70% in disease-specific mouse model using LNP-delivered CRISPR/Cas cargo.
Robust target protein upregulation with >80% reduction of disease-associated biomarker in mice.
In cynomolgus monkey hepatocytes: >50% target gene editing and >15-fold protein upregulation.
Company expects to disclose the disease target and development candidate later in 2025.
Data presented at ASGCT Annual Meeting; additional oral presentation at TIDES USA on May 21.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.